Curated News
By: NewsRamp Editorial Staff
January 30, 2026
VolitionRx Seeks French Reimbursement for Lung Cancer Blood Test
TLDR
- VolitionRx's reimbursement submission for Nu.Q Cancer assays in France could provide early market access advantage for lung cancer diagnostics ahead of competitors.
- VolitionRx is preparing a reimbursement submission for Nu.Q Cancer assays in France through the Innovative Procedures Outside the Nomenclature framework with Hospices Civils de Lyon support.
- VolitionRx's Nu.Q Cancer test aims to improve lung cancer survival rates and identify patients for curative care through earlier detection and monitoring.
- VolitionRx's epigenetics approach uses methylated nucleosome biomarkers to provide survival information for non-small cell lung cancer patients at diagnosis.
Impact - Why it Matters
This development matters because it represents a critical step toward making a potentially life-saving diagnostic tool more accessible. Lung cancer is a leading cause of cancer death worldwide, and early, accurate information about disease progression is crucial for treatment planning. If Volition's Nu.Q® Cancer test becomes a reimbursed part of routine care in France, it could help doctors better stratify patients—identifying those with more aggressive disease who need intensive therapy and those who might avoid overtreatment. This precision can improve survival rates and quality of life. Furthermore, success in France, a major European healthcare market, often paves the way for adoption in other countries, accelerating global access to innovative diagnostics. For patients and families facing a lung cancer diagnosis, tools that offer clearer prognostic insights can reduce uncertainty and guide more personalized, effective care.
Summary
VolitionRx Ltd., a multi-national epigenetics company trading on the NYSE American under the symbol VNRX, has announced a significant step toward integrating its Nu.Q® Cancer assays into France's healthcare system. The company is preparing a reimbursement submission to French government agencies, a process that will be actively supported by Hospices Civils de Lyon (HCL), France's second-largest university hospital system. This submission will run parallel to a previously announced clinical certification process at HCL, with the ultimate goal of introducing the Nu.Q® Cancer test into routine, reimbursed clinical practice for lung cancer management. The test measures methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis, with collaborative data indicating it can provide valuable information related to patient survival and disease progression, potentially helping identify those who could benefit most from curative care.
The reimbursement submission is expected to be filed under France's "Innovative Procedures Outside the Nomenclature" framework, a pathway designed to provide early reimbursement support for innovative medical procedures. Volition emphasizes that achieving reimbursement would represent a major milestone toward the routine clinical use of its Nu.Q® Cancer assays in France, which would in turn support broader commercialization efforts and potential licensing discussions in other global markets. This development is part of Volition's broader mission, as detailed on its website, to advance the science of epigenetics and develop simple, cost-effective blood tests for earlier detection and monitoring of diseases like cancer, aiming to save lives and improve patient outcomes.
The news was disseminated through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on the biotechnology and life sciences sectors. BioMedWire provides services like press release distribution and enhancement, article syndication, and social media distribution to help companies like Volition reach investors, journalists, and the public. This announcement underscores the growing intersection of innovative diagnostic technologies, healthcare reimbursement systems, and strategic corporate communications in bringing new medical solutions to market, with the potential to transform lung cancer care in France and beyond.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Seeks French Reimbursement for Lung Cancer Blood Test
